Antibiotic resistance: A current epilogue

Biochemical Pharmacology

Volumn 134, Issue , 2017, Pages 139-146

  Dodds, David R ^a  

^a Dodds and Associates LLC   (United States)

Author keywords

Advanced microbial resistance; Antibiotic growth promoters; Antibiotic resistance

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; DRUG RESEARCH; HISTORY OF MEDICINE; HUMAN; NON-THERAPEUTIC RESEARCH; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECTS; ISOLATION AND PURIFICATION; PENICILLIUM; PHYSIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; HUMANS; PENICILLIUM;

EID: 85008600479     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2016.12.005     Document Type: Review

References (96)

1. [1] Martin, G.S., Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev. Anti. Infect. Ther. 10:6 (2012), 701–706.
2. [2] Lesch, J.E., The First Miracle Drugs: How the Sulfa Drugs Transformed Medicine. 2007, Oxford University Press See reference 29 on page 84.
3. [3] Ehrlich, P., Beiträge zur Kenntniss der Anilinfärbungen und ihre Verwendung in der mikroskopischen Technik. Archiv für mikroskopische Anatomie 13 (1877), 263–277.
4. [4] Austrian, R., The gram stain and the etiology of lobar pneumonia, an historical note. Bacteriol. Rev. 24:3 (1960), 261–265.
5. [5] Gram, C., Über die isolirte Färbung der Schizomyceten in Schnitt- und Trockenpräparaten. Fortschritte der Medicin 2 (1884), 185–189.
6. [6] F. Mietzsch, J. Klarer, Verfahren zur Herstellung von Azoverbindungen, DE 607,537 filed 25 Dec. 1932.
7. [7] Henry, R.J., The mode of action of sulfonamides. Bacteriol. Rev. 7:4 (1943), 175–262.
8. [8] Bovet, D., Une Chimie qui Guérit. Histoire de la Découverte des Sulfamides. 1988, Payot Coll. Médecine et Sociétés, Paris p. 132–133.
9. [9] Tréfouël, J., Tréfouël, T., Nitti, F., Bovet, D., Activité du p-aminophénylsulfamide sur l'infection streptococcique expérimentale de la souris et du lapin. C. R. Soc. Biol., 120, 1935, 756.
10. [10] Gelmo, P., Über Sulfamide der p-Amidobenzolsulfonsäure. J. Prakt. Chem. 77 (1908), 369–382.
11. [11] Verfahren zur Darstellung von gelben Wollfarbstoffen, DE 226,239 filed 18 May, 1090. No inventors are listed on the patent.
12. [12] Title 21 Chapter 9 of the United States Code, “Federal Food, Drug, and Cosmetic Act”, http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/default.htm, (accessed August 1, 2016).
13. [13] Bentley, R., Different roads to discovery; prontosil (hence sulfa drugs) and penicillin (hence beta-lactams). J. Ind. Microbiol. Biotechnol. 36:6 (2009), 775–786.
14. [14] Fleming, A., On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br. J. Exp. Pathol. 10 (1929), 226–236.
15. [15] Chain, E., Florey, H.W., Gardner, A.D., Heatley, N.G., Jennings, M.A., Orr-Ewing, J., Sanders, A.G., Penicillin as a chemotherapeutic agent. Lancet ii (1940), 226–228.
16. [16] A. Fleming, “Penicillin” Nobel Lecture, December 11, 1945, https://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdf, (accessed August 1, 2016).
17. [17] Van Epps, H.L., René Dubos: unearthing antibiotics. J. Exp. Med., 203(2), 2006, 259.
18. [18] Avery, O.T., Dubos, R., The protective action of a specific enzyme against type III pneumococcus infection in mice. J. Exp. Med. 54:1 (1931), 73–89.
19. [19] Dubos, R.J., Studies on a bactericidal agent extracted from a soil bacillus: II. Protective effect of the bactericidal agent against experimental pneumococcus infections in mice. J. Exp. Med. 70:1 (1939), 11–17.
20. [20] Aldridge, Susan, Parascandola, John, The Discovery and Development of Penicillin, 1928–1945. Commerative booklet published Nov. 19, 1999, American Chemical Society and Royal Society of Chemistry.
21. [21] http://botit.botany.wisc.edu/toms_fungi/nov2003.html, “Tom Volk's Fungus of the Month for November 2003”, (accessed August 1, 2016).
22. [22] Quinn, R., Rethinking antibiotic research and development world war II and the penicillin collaborative. Am. J. Public Health 103:3 (2013), 426–434.
23. [23] http://www.syracuse.com/news/index.ssf/2013/09/bristol-myers_squibb_marks_completion_of_east_syracuse_plants_transformation.html (accessed August 1, 2016).
24. [24] Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research and Office of Surveillance and Epidemiology, “Drug Use Review 2015”, http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM319435.pdf, (accessed August 1, 2016).
25. [25] Armstrong, G.L., Conn, L.A., Pinner, R.W., Trends in infectious disease mortality in the United States during the 20th century. JAMA 281:1 (1999), 61–66.
26. [26] Department-Of Commerce And Labor ∼Bureau Of The Census, Mortality Statistics 1905, Sixth Annual Report, Washington, Government Printing Office, 1907.
27. [27] Centers for Disease Control and Prevention, Achievements in public health, 1900–1999: control of infectious diseases. Morb. Mortal. Wkly Rep. 48:29 (1999), 621–629 https://www.cdc.gov/mmwr/preview/mmwrhtml/mm4829a1.htm (accessed August 1, 2016).
28. [28] National Center for Health Statistics, Health, United States, 2015: With Special Feature on Racial and Ethnic Health Disparities. available at http://www.cdc.gov/nchs/data/hus/hus15.pdf#033, 2015 (accessed August 1, 2016).
29. [29] Fauci, A.S., Touchette, N.A., Folkers, G.K., Emerging infectious diseases: a 10-year perspective from the national institute of allergy and infectious diseases. Emerg. Infect. Dis. 11:4 (2005), 520–525.
30. [30] Morens, D.M., Folkers, G.K., Fauci, A.S., The challenge of emerging and re-emerging infectious diseases. Nature 430 (2004), 242–249.
31. [31] World Health Organization, The Top 10 Causes of Death, http://www.who.int/mediacentre/factsheets/fs310/en/index2.html; (accessed August 1, 2016).
32. [32] World Health Organization, Global Health Estinates Summary Tables, July 2013, http://www.who.int/healthinfo/global_burden_disease/en/; (accessed August 17, 2016).
33. [33] R. Minghui, WHO Assistant Director-General for HIV/AIDS, Tuberculosis, Malaria and Neglected Tropical Diseases, “Endemic Infectious Diseases: The Next 15 Years”, http://www.who.int/mediacentre/commentaries/2016/Endemic-infectious-diseases-next-15-years/en/; (accessed August 17, 2016).
34. [34] Hoena, A.G., Margos, G., Bent, S.J., Diuk-Wasser, M.A., Barbour, A., Kurtenbach, K., Fish, D., Phylogeography of Borrelia burgdorferi in the eastern United States reflects multiple independent lyme disease emergence events. Proc. Nat. Acad. Sci. 10:35 (2009), 15013–15018.
35. [35] Nash, D., Mostashari, F., Fine, A., Miller, J., O'Leary, D., Murray, K., et al. The outbreak of West Nile Virus infection in the New York City area in 1999. N. Engl. J. Med. 344:24 (2001), 1807–1814.
36. [36] Reimann, C.A., Hayes, E.B., DiGuiseppi, C., Hoffman, R., Lehman, J.A., Lindsey, N., et al. Epidemiology of neuroinvasive arboviral disease in the United States, 1999–2007. Am. J. Trop. Med. Hyg. 79:6 (2008), 974–979.
37. [37] Baron, R.C., Mccormick, J.B., Zubeir, O.A., Ebola virus disease in Southern Sudan: hospital dissemination and intrafamilial spread. Bull. World Health Organ. 61:6 (1983), 997–1003.
38. [38] Wells, J.G., Davis, B.R., Wachsmuth, I.K., Riley, L.W., Remis, R.S., Sokolow, R., Morris, G.K., Laboratory investigation of hemorrhagic colitis outbreaks associated with a rare Escherichia coli serotype. J. Clin. Microbiol. 18:3 (1983), 512–520.
39. [39] Riley, L.W., Remis, R.S., Helgerson, S.D., McGee, H.B., Wells, J.G., Davis, B.R., Hebert, R.J., Olcott, E.S., Johnson, L.M., Hargrett, N.T., Blake, P.A., Cohen, M.L., Hemorrhagic colitis associated with a rare Escherichia coli serotype. N. Engl. J. Med. 308:12 (1983), 681–685.
40. [40] Fauci, A.S., Touchette, N.A., Folkers, G.K., Emerging infectious diseases: a 10-year perspective from the national institute of allergy and infectious diseases. Emerg. Infect. Dis., 11(4), 2005 http://wwwnc.cdc.gov/eid/article/11/4/04-1167, (accessed August 1, 2016).
41. [41] Sikka, V., Chattu, V.K., Popli, R.K., Galwankar, S.C., Kelkar, D., Sawicki, S.G., et al. The emergence of Zika virus as a global health security threat: a review and a consensus statement of the INDUSEM Joint working Group (JWG). J. Global Infect. Dis. 8:1 (2016), 3–15.
42. [42] World Health Organization, “Third WHO Report On Neglected Tropical Diseases, 2015”, http://www.who.int/neglected_diseases/9789241564861/en/, (accessed August 1, 2016).
43. [43] World Health Organization, “World Health Statistics 2015”, http://www.who.int/gho/publications/world_health_statistics/2015/en/, (accessed August 1, 2016).
44. [44] H.L. Dunn, U. S. Department Of Health, Education, And Welfare, “Vital Statistics Of The United States 1952, Volume 1” United States Government Printing Office, Washington: 1955, available at https://www.cdc.gov/nchs/data/vsus/VSUS_1952_1.pdf, (accessed August 1, 2016).
45. [45] Centers for Disease Control and Prevention, “2016 Nationally Notifiable Infectious Diseases”, https://wwwn.cdc.gov/nndss/conditions/notifiable/2016/infectious-diseases/, (accessed August 23, 2016).
46. [46] Martin, G.S., Mannino, D.M., Eaton, S., Moss, M., The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348 (2003), 1546–1554.
47. [47] Jawad, I., Lukšić, I., Rafnsson, S.B., Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. J. Global Health 2:1 (2012), 1–9 www.jogh.org, doi: 10.7189/jogh.02.010404.
48. [48] Levy, M.M., Dellinger, R.P., Townsend, S.R., Linde-Zwirble, W.T., Marshall, J.C., Bion, J., et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med. 36 (2010), 222–231.
49. [49] Herold, B.C., Immergluck, L.C., Maranan, M.C., Lauderdale, D.S., Gaskin, R.E., Boyle-Vavra, S., et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 279:8 (1998), 593–598.
50. [50] Centers for Disease Control and Prevention, Nosocomial Enterococci resistant to Vancomycin-United States, 1989–1993. Morb. Mortal. Wkly Rep. 42:30 (1993), 597–599 http://www.cdc.gov/mmwr/preview/mmwrhtml/00021331.htm, (accessed August 1, 2016).
51. [51] Cetinkaya, Y., Falk, P., Mayhall, C.G., Vancomycin-Resistant Enterococci. Clin. Microbiol. Rev. 13:4 (2000), 686–707.
52. [52] Centers for Disease Control and Prevention, Extensively drug-resistant tuberculosis-United States, 1993–2006. Morb. Mortal. Wkly Rep. 56:11 (2007), 250–253.
53. [53] World Health Organization, “Antimicrobial Resistance: Global Report on Surveillance 2014”, http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf, (accessed August 1, 2016).
54. [54] Centers for Disease Control and Prevention, “Antibiotic/Antimicrobial Resistance: Biggest Threats. 2015” https://www.cdc.gov/drugresistance/biggest_threats.html, (accessed August 1, 2016).
55. [55] World Health Organization, “Fact Sheet: Antimicrobial Resistance”. September 2016, http://www.who.int/mediacentre/factsheets/fs194/en/, (accessed September 21, 2016).
56. [56] Tillotson, G.S., Antibiotic development: a victim of market forces?. IDrugs 11:5 (2008), 340–346.
57. [57] Shlaes, D.M., The abandonment of antibacterials: why and wherefore?. Curr. Opin. Pharmacol. 3:5 (2003), 470–473.
58. [58] Alanis, A.J., Resistance to antibiotics: are we in the post-antibiotic era?. Arch. Med. Res. 36:6 (2005), 697–705.
59. [59] Gootz, T.D., The global problem of antibiotic resistance. Crit. Rev. Immunol. 30:1 (2010), 79–93.
60. [60] Overbye, K.M., Barrett, J.F., Antibiotics: where did we go wrong?. Drug Discovery Today 10:1 (2005), 45–52.
61. [61] Projan, S.J., Why is pharma getting out of antibiotics?. Curr. Opin. Microbiol. 6:5 (2003), 427–430.
62. [62] O'Neill Commission, “Survey Of Actors Involved In The Development Of Antimicrobials: High Level Results – February 2015”, supporting document for “Tackling A Global Health Crisis: Initial Steps”, 5 February 2015, (available online at http://amr-review.org/Publications, accessed September 1, 2016).
63. [63] The reports of the O'Neill Commission are available online at http://amr-review.org/Publications, (all accessed September 1, 2016).“Infection Prevention, Control And Surveillance: Limiting The Development And Spread Of Drug-Resistance”, 22 March 2016.“Vaccines And Alternative Approaches: Reducing Our Dependence On Antimicrobials”, 11th February 2016.“Antimicrobials In Agriculture And The Environment: Reducing Unnecessary Use And Waste”, 8 December 2015.“Rapid Diagnostics: Stopping Unnecessary Use Of Antibiotics”, October 23, 2015.“Securing New Drugs for Future Generations – the Pipeline of Antibiotics”, May 14, 2015.“Antimicrobial Resistance: Tackling a Crisis for the Future Health and Wealth of Nations”, December 11, 2014.
64. [64] When The Drugs Don't Work, The Economist, 2016 pages 9, and 19–21.
65. [65] President's Council of Advisors onScience and Technology, “Report To The President On Combating Antibiotic Resistance”, September 2014, available online at https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_amr_jan2015.pdf, (accessed August 1, 2016).
66. [66] Infectious Diseases Society of America, Combating antimicrobial resistance: policy recommendations to save lives. Clin. Infect. Dis. 52:Suppl. 5 (2011), S397–S428.
67. [67] Spellberg, B., Guidos, R., Gilbert, D., Bradley, J., Boucher, H.W., Scheld, W.M., et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the infectious diseases society of America. Clin. Infect. Dis. 46:2 (2008), 155–164.
68. [68] Moore, P.R., Evenson, A., Luckey, T.D., Mccoy, E., Elvehjem, C.A., Hart, E.B., Use of sulfasuxidine, streptothricin, and streptomycin in nutritional studies with the chick. J. Biol. Chem. 165:2 (1946), 437–441.
69. [69] Stokstad, E.L.R., Jukes, T.H., Pierce, J., Page, A.C., Franklin, A.L., The multiple nature of the animal protein factor. J. Biol. Chem. 180 (1949), 647–654.
70. [70] Stockstad, E.L.R., Jukes, T.H., Further observations on the animal protein factor. Proc. Soc. Exp. Biol. Med. 73 (1950), 523–528.
71. [71] Gustafson, R.H., Kiser, J.S., Nonmedical uses of the tetracyclines. Hlavka, J.J., Booth, J.H., (eds.) The Tetracyclines, 1985, Springer Verlag, 405–446 Chapter 8.
72. [72] Page, S.W., The Role of Enteric Antibiotics in Livestock Production. 2003, Avcare Limited 0-9750845-0-X.
73. [73] Eyssen, H., de Somer, D.P., The mode of action of antibiotics in stimulating growth of chicks. J. Exp. Med. 117:1 (1963), 127–138.
74. [74] Matterson, L.D., Singsen, E.P., Comparison of several antibiotics as growth stimulants in practical chick-starting rations. Agric. Exp. Sta. Bull., 275, 1951, 20.
75. [75] Swann MM, 1969. “Report, Joint Committee on the use of Antibiotics in Animal Husbandry and Veterinary Medicine”, HMSO, London, summary available at http://www.publications.parliament.uk/pa/ld199798/ldselect/ldsctech/081vii/st0706.htm, (accessed August 13, 2016).
76. [76] Martel, A., Devriese, L.A., Cauwerts, K., De Gussem, K., Decostere, A., Haesebrouck, F., Susceptibility of Clostridium perfringens strains from broiler chickens to antibiotics and anticoccidials. Avian Pathol. 33 (2004), 3–7.
77. [77] Callaway, T.R., Edrington, T.S., Rychlik, J.L., Genovese, K.J., Poole, T.L., Jung, Y.S., et al. Ionophores: their use as ruminant growth promotants and impact on food safety. Curr. Issues Intest. Microbiol. 4:2 (2003), 43–51.
78. [78] Russell, J.B., Houlihan, A.J., Ionophore resistance of ruminal bacteria and its potential impact on human health. FEMS Microbiol. Rev. 27 (2003), 65–74.
79. [79] Hays, V.W., The Hays Report: Effectiveness of Feed Additive Usage of Antibacterial Agents in Swine and Poultry Production. 1981, Office of Technology Assessment, US Congress, Washington DC, and Rachelle Laboratories, Long Beach, CA.
80. [80] Graham, J.P., Boland, J.J., Silbergeld, E., Growth promoting antibiotics in food animal production: an economic analysis. Public Health Rep. 122 (2007), 79–87.
81. [81] Zimmerman, D.R., Role of subtherapeutic levels of antimicrobials in pig production. J. Anim. Sci. 62:Suppl. 3 (1986), 6–17.
82. [82] Hays, V.W., Batson, D., Gerrits, R., Public health implications of the use of antibiotics in animal agriculture – preface. J. Anim. Sci. 62:Suppl. 3 (1986), 1–4.
83. [83] Dibner, J.J., Richards, J.D., Antibiotic growth promoters in agriculture: history and mode of action. Poult. Sci. 84 (2005), 634–643.
84. [84] Martin, M.J., Thottathil, S.E., Newman, T.B., Antibiotics overuse in animal agriculture: a call to action for health care providers. Am. J. Public Health 105:12 (2015), 2409–2410.
85. [85] Yap, M.-N.F., The Double Life of Antibiotics. Mo. Med. 110:4 (2013), 320–324.
86. [86] Food and Drug Administration, Department of Health and Human Services, “2011 Summary Report On Antimicrobials Sold or Distributed for Use in Food-Producing Animals”, September 2014, http://www.fda.gov/downloads/ForIndustry/UserFees/AnimalDrugUserFeeActADUFA/UCM338170.pdf, (accessed August 1, 2016).
87. [87] Food and Drug Administration, Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, “Drug Use Review”, April 5, 2012, http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM319435.pdf, (accessed August 23, 2016).
88. [88] Food and Drug Administration, Department of Health and Human Services, “2014 Summary Report On Antimicrobials Sold or Distributed for Use in Food-Producing Animals”, December 2015, http://www.fda.gov/downloads/ForIndustry/UserFees/AnimalDrugUserFeeActADUFA/UCM476258.pdf, (accessed August 1, 2016).
89. [89] Food and Drug Administration, Department of Health and Human Services, “2013 Summary Report On Antimicrobials Sold or Distributed for Use in Food-Producing Animals”, April 2015, www.fda.gov/downloads/ForIndustry/UserFees/AnimalDrugUserFeeActADUFA/UCM440584.pdf, (accessed August 23, 2016).
90. [90] European Medicines Agency, European Surveillance of Veterinary Antimicrobial Consumption, 2015, “Sales Of Veterinary Antimicrobial Agents In 26 EU/EEA Countries In 2013” (EMA/387934/2015), http://www.ema.europa.eu/docs/en_GB/document_library/Report/2015/10/WC500195687.pdf, (accessed August 23, 2016).
91. [91] Alliance to Save Our Antibiotics, “Antimicrobial Resistance – Why The Irresponsible Use Of Antibiotics In Agriculture Must Stop” published online June 2015, https://www.ciwf.org.uk/media/7247793/antibiotics-alliance-40pp-report-2015.pdf, (accessed August 1, 2016).
92. [92] Meek, R.W., Vyas, H., Piddock, L.J.V., Nonmedical uses of antibiotics: time to restrict their use?. PLoS Biol., 13(10), 2015, e1002266 http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002266, (accessed August 1, 2016).
93. [93] “Antibiotics In Animal Farming Public Health And Animal Welfare”, November 2011, http://www.fao.org/fileadmin/user_upload/animalwelfare/antibiotics_in_animal_farming.pdf, (accessed August 23, 2016).
94. [94] O'Neill Commission, “Tackling Drug-Resistant Infections Globally: Final Report and Recommendations”, May 19, 2016, (available online at http://amr-review.org/Publications, accessed September 1, 2016).
95. [95] R. Smith, J. Coast, “The True Cost Of Antimicrobial Resistance.”, BMJ (Clinical Research ed), (2013) 346:f1493 (available at http://researchonline.lshtm.ac.uk/660655/, accessed August 1, 2016).
96. [96] Sarkar, P., Gould, I.M., Antimicrobial agents are societal drugs: how should this influence prescribing?. Drugs 66:7 (2006), 893–901.